ImpediMed Limited

ASX:IPD Stock Report

Market Cap: AU$107.2m

ImpediMed Valuation

Is IPD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of IPD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate IPD's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate IPD's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IPD?

Key metric: As IPD is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for IPD. This is calculated by dividing IPD's market cap by their current revenue.
What is IPD's PS Ratio?
PS Ratio10.6x
SalesAU$10.32m
Market CapAU$107.25m

Price to Sales Ratio vs Peers

How does IPD's PS Ratio compare to its peers?

The above table shows the PS ratio for IPD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average13.3x
OIL Optiscan Imaging
44.8xn/aAU$133.7m
CYC Cyclopharm
6.3x42.7%AU$152.8m
AHC Austco Healthcare
1.5xn/aAU$87.4m
SOM SomnoMed
0.6x9.0%AU$52.9m
IPD ImpediMed
10.6x41.0%AU$109.3m

Price-To-Sales vs Peers: IPD is good value based on its Price-To-Sales Ratio (10.6x) compared to the peer average (13.3x).

Price to Sales Ratio vs Industry

How does IPD's PS Ratio compare vs other companies in the AU Medical Equipment Industry?

8 CompaniesPrice / SalesEstimated GrowthMarket Cap
SDI SDI
1.1x5.4%US$79.03m
SOM SomnoMed
0.6x9.0%US$34.51m
CMP Compumedics
1xn/aUS$34.05m
NXS Next Science
1.2x30.6%US$27.14m
IPD 10.6xIndustry Avg. 3.1xNo. of Companies11PS0612182430+
8 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: IPD is expensive based on its Price-To-Sales Ratio (10.6x) compared to the Australian Medical Equipment industry average (3.1x).

Price to Sales Ratio vs Fair Ratio

What is IPD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IPD PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio10.6x
Fair PS Ratio15.6x

Price-To-Sales vs Fair Ratio: IPD is good value based on its Price-To-Sales Ratio (10.6x) compared to the estimated Fair Price-To-Sales Ratio (15.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst IPD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentAU$0.054
AU$0.15
+169.8%
27.0%AU$0.19AU$0.09n/a4
Nov ’25AU$0.055
AU$0.15
+164.9%
27.0%AU$0.19AU$0.09n/a4
Oct ’25AU$0.059
AU$0.15
+158.0%
26.4%AU$0.20AU$0.09n/a4
Sep ’25AU$0.048
AU$0.16
+243.1%
13.9%AU$0.20AU$0.14n/a4
Aug ’25AU$0.06
AU$0.17
+178.1%
14.2%AU$0.20AU$0.14n/a4
Jul ’25AU$0.071
AU$0.18
+146.9%
15.0%AU$0.20AU$0.14n/a4
Jun ’25AU$0.076
AU$0.18
+130.7%
15.0%AU$0.20AU$0.14n/a4
May ’25AU$0.08
AU$0.18
+119.2%
15.0%AU$0.20AU$0.14n/a4
Apr ’25AU$0.092
AU$0.18
+97.1%
16.2%AU$0.20AU$0.14n/a3
Mar ’25AU$0.093
AU$0.18
+95.0%
16.2%AU$0.20AU$0.14n/a3
Feb ’25AU$0.10
AU$0.22
+105.5%
16.2%AU$0.26AU$0.18n/a3
Jan ’25AU$0.14
AU$0.22
+51.7%
15.5%AU$0.26AU$0.18n/a3
Dec ’24AU$0.14
AU$0.22
+57.1%
15.5%AU$0.26AU$0.18n/a3
Nov ’24AU$0.10
AU$0.27
+159.2%
30.6%AU$0.39AU$0.21AU$0.0553
Oct ’24AU$0.17
AU$0.23
+29.1%
52.4%AU$0.39AU$0.06AU$0.0594
Sep ’24AU$0.17
AU$0.23
+32.9%
52.4%AU$0.39AU$0.06AU$0.0484
Aug ’24AU$0.20
AU$0.24
+22.6%
49.6%AU$0.39AU$0.06AU$0.064
Jul ’24AU$0.18
AU$0.17
-8.3%
37.0%AU$0.21AU$0.06AU$0.0714
Jun ’24AU$0.14
AU$0.17
+18.0%
37.0%AU$0.21AU$0.06AU$0.0764
May ’24AU$0.17
AU$0.16
-1.5%
38.3%AU$0.23AU$0.06AU$0.084
Apr ’24AU$0.10
AU$0.18
+74.6%
19.6%AU$0.23AU$0.14AU$0.0923
Mar ’24AU$0.061
AU$0.15
+141.3%
47.1%AU$0.23AU$0.04AU$0.0934
Feb ’24AU$0.061
AU$0.17
+170.6%
56.4%AU$0.30AU$0.04AU$0.104
Jan ’24AU$0.079
AU$0.18
+126.3%
51.7%AU$0.30AU$0.04AU$0.144
Dec ’23AU$0.092
AU$0.18
+94.3%
51.7%AU$0.30AU$0.04AU$0.144
Nov ’23AU$0.092
AU$0.18
+94.3%
51.7%AU$0.30AU$0.04AU$0.104

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

SDI

AU$122.4m

Engages in the research and development, manufacture, and marketing of dental restorative materials, whitening systems, and other dental materials in Australia, Europe, the United States, and Brazil.

SDI

AU$1.02

7D

0%

1Y

22.9%

Doctor Care Anywhere Group

AU$25.7m

Provides digital healthcare and development services in the United Kingdom, Australia, and the Republic of Ireland.

DOC

AU$0.065

7D

-3.0%

1Y

32.7%

Nova Eye Medical

AU$36.6m

Designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally.

EYE

AU$0.16

7D

3.2%

1Y

14.3%